Latest news

Improved grip strength and hand function demonstrated in preliminary data from the iHand study

First participant included in research project on the effect of exoskeletons on the central nervous system

World’s first soft robotic muscle strengthening system. Developed in collaboration with leading Fortune 500 companies

Menu

26 Nov, 2021  ·  Regulatory information

Bioservo engages Erik Penser Bank AB as liquidity provider

Bioservo Technologies AB will, starting from 4 December 2021, change liquidity provider to Erik Penser Bank AB. 

In its assignment as liquidity provider, Erik Penser Bank AB will ensure the opportunity to trade in the company's shares by continuously placing trading items on each buy and sell page in the order book. This is in accordance with Nasdaq First North Growth Market regulations regarding liquidity provision and means that the liquidity provider quotes the purchase and sale volume corresponding to at least SEK 15,000 with a spread of a maximum of 4% between the buy and sell price. The purpose of the liquidity provision is to improve the liquidity of the share and reduce the difference between the bid and ask price during ongoing trading.

Until the transition, Lago Kapital LTD will continue to act as a liquidity provider for Bioservo Technologies.

For more information, please contact:
Petter Bäckgren, CEO
petter.backgren@bioservo.com
+46 8 21 17 10
or
Madeleine Börjesson, CFO
madeleine.borjesson@bioservo.com
+46 8 21 17 10

 

Note: This information is such as is required by Bioservo Technologies AB under the EU Market Abuse Regulation. The information was submitted, through the care of the above person, for publication on 26 November 2021 at 17:30 (CET).


About Bioservo Technologies
Bioservo Technologies AB (publ) is a world leading company in wearable muscle strengthening systems for people in need of extra strength and endurance. All our innovative products and systems are designed to keep people strong, healthy, and efficient.

The company has a unique global position within soft exoskeleton technology for the hand, both for industrial applications to improve the health for workers and to improve quality of life for people with reduced muscle strength.

Bioservo Technologies was founded in 2006 in collaboration between researchers at the Royal Institute of Technology and a doctor at Karolinska University Hospital. Bioservo Technologies is a Swedish public limited company with headquarters in Stockholm.

FNCA Sweden AB, +46(0)8-52800399, info@fnca.se is the company’s Certified Adviser on Nasdaq First North
For more information, please visit www.bioservo.com